Transcode Therapeutics, Inc.
RNAZ· Nasdaq
RNAZTranscode Therapeutics, Inc.
Filed May 15, 2026 · 10-Q · 45 days after period end · 0001104659-26-062535
| Metric | Q1 2026 | Q1 2025 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$17.79M | -$12.09M | -$3.47M | -$4.49M |
| EPS Diluted | -$21.28 | -$70.16 | -$0.27 | -$0.97 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Transcode Therapeutics, Inc. · CIK 1829635 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end
